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We have developed a novel Neisseria meningitidis serogroup-specific loop-mediated
isothermal amplification (LAMP) assay for six of the most common meningococcal
serogroups (A, B, C, W, X, and Y). The assay was evaluated using a set of 31
meningococcal LAMP assay positive cerebrospinal fluid (CSF) specimens from 1574
children with suspected meningitis identified in prospective surveillance between 1998
and 2002 in Vietnam, China, and Korea. Primer specificity was validated using 15
N. meningitidis strains (including serogroups A, B, C, E, W, X, Y, and Z) and 19 non-
N. meningitidis species. The N. meningitidis serogroup LAMP detected down to ten
copies and 100 colony-forming units per reaction. Twenty-nine CSF had N. meningitidis
serogroup identified by LAMP compared with two CSF in which N. meningitidis
serogroup was identified by culture and multi-locus sequence typing. This is the first
report of a serogroup-specific identification assay for N. meningitidis using the LAMP
method. Our results suggest that this assay will be a rapid, sensitive, and uniquely
serogroup-specific assay with potential for application in clinical laboratories and public
health surveillance systems.
Keywords: Neisseria meningitidis, serogroup identification, loop-mediated isothermal amplification, meningitis,
cerebrospinal fluid, children
INTRODUCTION
Neisseria meningitidis is a gram-negative β-proteobacterium and member of the bacterial family
Neisseriaceae (Stephens et al., 2007). The meningococcal polysaccharide capsule and outer
membrane proteins have been identiﬁed as N. meningitidis virulence factors (Stephens, 2009).
N. meningitidis is principally subdivided into 12 serogroups based on the capsular polysaccharide
type (A, B, C, E, H, I, K, L, W, X, Y, and Z; Harrison et al., 2013). Globally, the majority of invasive
meningococcal disease has been attributable to six serogroups designated A, B, C, W, X, and Y
(Stephens et al., 2007; Stephens, 2009; Verma and Khanna, 2012).
Abbreviations: Nm-LAMP, meningococcal LAMP.
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The geographic distribution and epidemic potential of
N. meningitidis may vary by serogroup. In Europe and other
industrialized countries, serogroups B and C are major causes
of invasive meningococcal disease (Harrison et al., 2009). The
majority of meningococcal disease in European countries, which
ranges in incidence from 0.2 to 14 cases per 100,000 (Harrison
et al., 2009), is caused by serogroup B strains, particularly
in countries that have introduced meningococcal serogroup C
conjugate vaccines. More recent reports have noted increases
in serogroup W and Y meningococcal disease (Campbell et al.,
2009; Ladhani et al., 2012). In the Americas, the majority
of meningococcal disease is caused by serogroups B and C
(Stephens et al., 2007). The emergence of serogroup W and
Y has been noted in some countries where surveillance is
present (Chiavetta et al., 2007). In Africa, N. meningitidis is
the leading cause of severe, life-threatening meningitis and has
been responsible for thousands of cases and scores of deaths
across sub-Saharan meningitis belt countries (Alonso et al.,
2006). Seasonal large-scale epidemics caused by N. meningitidis
serogroup A have been frequent in Sub-Saharan Africa ranging
from Senegal to Ethiopia (WHO, 2011). The introduction of
meningococcal serogroup A conjugate vaccines in countries
of Sub-Saharan Africa has led to signiﬁcant reductions in
serogroup A epidemics (Kristiansen et al., 2014). Serogroup
C, serogroup X and, most recently, serogroup W disease have
also been reported (Harrison et al., 2009). The emergence of
serogroup W meningococcal disease in Africa was associated
with a large epidemic among Hajj pilgrims in 2000 and a
large-scale meningitis outbreak in Burkina Faso during 2002
(Alonso et al., 2006). In Asia, serogroup B has been identiﬁed
as the leading cause of meningococcal disease in Thailand and
Taiwan (Harrison et al., 2009). N. meningitidis serogroups A,
C, X, and Y have been identiﬁed in these and other Asian
countries (Stephens et al., 2007; Harrison et al., 2009; Kim et al.,
2012b).
Traditionally, invasive disease due to N. meningitidis has
been diagnosed using specialized bacterial culture media and
reagents (e.g., anti-sera) used for identifying N. meningitidis
serogroups (Corless et al., 2001). While traditional gram
staining and observation using light microscopy are used
for N. meningitis detection, these techniques do not permit
serogroup identiﬁcation (Chanteau et al., 2006). The diagnosis
of N. meningitidis invasive disease by culture testing requires a
well-equipped laboratory with appropriate biosafety equipment
and procedures (Borrow et al., 2014). In some settings, rapid
immunochromatographic antigen detection testing has been
applied for detection of N. meningitidis but these assays are
limited by relatively low diagnostic sensitivity (Chanteau et al.,
2006). Traditional diagnostic assays also have limited utility in
many populations and health systems where inappropriate use
of antibiotics continues despite global increases in antibiotic
resistance (Levy and Marshall, 2004). In such settings, detection
of N. meningitidis may be problematic due to inhibition of
bacterial growth due to antibiotics present in human clinical
samples (Laxminarayan et al., 2013). In such cases, isolation
of bacteria from patients’ cerebrospinal ﬂuid (CSF) is time-
consuming and may yield little or no growth.
Given the geographic and temporal variations in
meningococcal strains causing both epidemic and sporadic
disease, the serogroup identiﬁcation ofN. meningitidis to identify
circulating serogroups is important as a part of disease control
and surveillance programs. Eﬀorts to improve diagnostics
for N. meningitidis have included development of a rapid
immunochromatographic assay that uses monoclonal antibodies
against polysaccharides for identiﬁcation of serogroups A,
W, C, and Y. Use of this assay has been most prominent in
endemic regions of Africa (Chanteau et al., 2006). A number
of PCR-based methods have been developed to identify major
N. meningitidis serogroups by targeting the polysialyltransferase
siaD gene or other genes involved in serogroup-speciﬁc capsule
synthesis (Taha et al., 2005; Fraisier et al., 2009). In addition,
real-time and multiplex PCR assays for serogroup identiﬁcation
of N. meningitidis have been developed (Fraisier et al., 2009; Zhu
et al., 2012; Doyle and Jennison, 2013). However, equipment
required for conventional and real-time PCR assays is relatively
expensive, and PCR methods are complex to perform in
resource-limited laboratory settings found in many developing
countries where N. meningitidis infections have been reported.
The loop-mediated isothermal ampliﬁcation (LAMP) method
(Notomi et al., 2000, 2015) oﬀers an attractive alternative to
bacterial cultivation and PCR. The LAMP assay uses four
diﬀerent primers to identify six distinct regions on the target
gene, resulting in a greater speciﬁcity than conventional PCR.
Additional primers (i.e., the loop primers designated LF and LB)
designed to anneal the loop structure in LAMP can be used to
increase sensitivity and speciﬁcity of the LAMP reaction (Tomita
et al., 2008). During the LAMP reaction, a small amount of DNA
can be detected due to the high ampliﬁcation capacity of the
assay. In addition, the LAMP assay does not require the use
of complicated procedures, equipment, or machines. For these
reasons, the LAMP assay is considered more rapid, eﬃcient,
simpler, and more economical than other diagnostic methods.
Recently, we developed a LAMP-based assay (Lee et al.,
2015) that demonstrated high sensitivity and speciﬁcity for
N. meningitidis detection in CSF. In the present study, we report
the development of a LAMP-based N. meningitidis serogroup
identiﬁcation assay and the evaluation of this assay’s ability to
detect speciﬁc N. meningitidis serogroups in CSF. This is the ﬁrst
report of N. meningitidis serogroup-speciﬁc identiﬁcation using
the LAMPmethod.
MATERIALS AND METHODS
Bacterial Strains
This study used 35 standard reference strains, including
15 N. meningitidis; serogroups A (HY0001 and NIID1),
B (HY0002, H44/76, and NIID2), C (HY0003 and NIID3),
E (NIID8), W (HY0006 and NIID93), X (HY0004 and NIID4),
Y (HY0005 andNIID5), and Z (NIID6): nine non-meningococcal
Neisseria species; N. gonorrhoeae NIID9, N. flavescens NIID10,
N. denitrificans NIID11, N. elongata NIID12, N. canis
NIID13, N. cinerea NIID14, N. lactamica NIID85, N. mucosa
NIID16, and N. sicca NIID17: and 10 other bacterial strains;
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Streptococcus pneumoniae ATCC 49619, Staphylococcus
aureus ATCC 29212, Klebsiella pneumoniae ATCC 700603,
K. oxytoca ATCC 700324, Pseudomonas aeruginosa ATCC
27853, Escherichia coli ATCC 25922, Enterococcus faecalis
ATCC 700324, Mycobacterium tuberculosis ATCC 27294, and
Haemophilus influenzaeATCC 9007 and IID984 (Lee et al., 2015;
Supplemental Materials, Table 1).
For the detection limit study; we used six N. meningitidis
strains; serogroups A (HY0001), B (HY0002), C (HY0003),
W (HY0006), X (HY0004), and Y (HY0005). Bacterial colony
forming unit (CFU) was determined as follows: bacteria were
inoculated on chocolate agar culture plate (Becton, Dickinson &
Co., Franklin Lakes, NJ, USA) and further incubated in 5% CO2
at 37◦C for 24 h. The bacteria were collected in 1 ml PBS and
CFUs were determined by serial dilutions of culture suspensions
inoculated on chocolate agar plate.
Preparation of Chromosomal DNA
Genomic DNA was extracted from the 35 standard reference
strains by the phenol-chloroform method (Lee et al., 2015). For
detection limit analysis, genomic DNAs from N. meningitidis
serogroups A (HY0001), B (HY0002), C (HY0003), W (HY0006),
X (HY0004), and Y (HY0005) were used, and the concentration
was determined using a NanoDrop 1000 (Thermo Fisher
Scientiﬁc, Inc., Waltham, MA, USA). Approximately 2.5
fg/2 μl of a DNA template was taken as one copy of the
N. meningitidis genome per reaction, based on the genome of
N. meningitidis serogroup B strain MC58 [accession number
AE002098; 2272351 bp (Tettelin et al., 2000)]. To ascertain the
detection limit of the LAMP assay, serial 10-fold dilutions of
the genomic DNA were tested in each LAMP reaction, and the
results were compared with those of each culture test as described
previously (Kim et al., 2012b).
For the detection limit study, triplicate LAMP testing was
performed using 10-fold dilutions of genomic DNA. Two
technicians tested the same samples independently to conﬁrm
the reproducibility of LAMP results as described previously (Kim
et al., 2012a; Lee et al., 2015).
LAMP Primer Design
Using PrimerExplorer V4 software1, we designed six serogroup
identiﬁcation LAMP primer sets (Table 1) targeting the
genome sequence of each serogroup-speciﬁc gene identiﬁed
(Taha et al., 2005; Fraisier et al., 2009): sacB (GenBank
accession number FR774048) for serogroup A, siaD
(GenBank accession number CP002424) for serogroup B,
siaD (GenBank accession number AM421808) for serogroup
C, synG (GenBank accession number AY234197) for
serogroup W, ctrA (GenBank accession number AY289931)
for serogroup X, and synF (GenBank accession number
AY234201)for serogroup Y.
Due to a high level of sequence identity between synF and
synG genes (Zhu et al., 2012; Doyle and Jennison, 2013), we
used the LAMP method along with an ampliﬁcation refractory
mutation system (ARMS; Newton et al., 1989; Ikeda et al.,
1https://primerexplorer.jp/lamp4.0.0/index.html
2007) to detect the speciﬁc sequences of synF (Table 1). The
ARMS uses uniquely designed primers that enable detection
of mutations (Newton et al., 1989). As a target of the present
investigation, we chose two speciﬁc sequences of the serogroup
Y synF gene. Based on the principle of ARMS, one of the
two speciﬁc sequences was designed in the 5′ end of the BIP
primer, and the other was designed in the second sequence
of the 5′ end of the FIP primer (Table 1). We then added
one mutation in the third sequence of the 5′ end of the
BIP primer (from G to C), and an additional mutation
in the fourth sequence of the 5′ end of the FIP primer
(from C to G).
LAMP and PCR Reactions
The LAMP reaction was performed with 25 μl of a mixture
containing 1.6 μM each of primers FIP and BIP, 0.2 μM
of primers F3 and B3, 0.4 μM of primers LF and LB, 8 U
of the Bst DNA polymerase large fragment (New England
Biolabs, Ipswich, MA, USA), 1.4 mM each of the four
deoxynucleoside triphosphates, 0.8 M betaine, 20 mM Tris-HCl
(pH 8.8), 10 mM KCl, 10 mM (NH4)2SO4, 8 mM MgSO4,
0.1% Tween 20, and 2 μl of template. The high-performance
liquid chromatography-puriﬁed primers were dissolved in
Tris-EDTA buﬀer. The mixture was incubated at 63–65◦C
(Table 1) for 60 min and then heated at 80◦C for 2 min
to terminate the reaction. For the detection limit study,
PCR was performed as described previously (Fraisier et al.,
2009).
Analysis of LAMP Products
Neisseria meningitidis serogroup detection was observed by
the visual inspection based on its generation of turbidity
proportional to the amount of ampliﬁed DNA (Mori et al.,
2004; Lee et al., 2015). A Loopamp real-time turbidimeter (LA-
200 real-time turbidimeter; Eiken Chemical, Co., Ltd., Tokyo,
Japan) was used to monitor the turbidity in the reaction
tube in real-time by reading the OD650 every 6 s. According
to the manufacturer’s protocol (Mori et al., 2004), we used
the application software for the turbidimeter to obtain the
ampliﬁcation time required to exceed a turbidity level of 0.1
(Tt). For the detection limit and speciﬁcity study, we also used
electrophoretic analysis and a colorimetric visual inspection
dye, Leuco Crystal Violet (LCV; D-Quick; Kaneka, Co., Ltd.,
Osaka, Japan; Miyamoto et al., 2015). LCV was dried down in
the caps of the reaction tubes. After reactions were completed,
the LAMP amplicons were mixed by inverting the tubes,
and changes in color were observed to obtain test results
(negative, remained colorless; positive, color change to blue:
Figure 1).
To verify the structure of LAMP ampliﬁed products, the
ampliﬁed LAMP products were sequenced using a BigDye
Terminator v. 3.1 cycle sequencing kit (Applied Biosystems,
Foster City, CA, USA) and an ABI PRISM 377 DNA
sequencer (Applied Biosystems) according to the manufacturer’s
instructions (Kim et al., 2012a; Lee et al., 2015). The target region
was between F2 and B2, and the primer sequences were from the
F2 and B2 regions.
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TABLE 1 | Loop-mediated isothermal amplification (LAMP) primer sets for serogroup identification of N. meningitidis.
Serogroup primer name Primer sequence Length (base pairs)
Serogroup A Sequence 5′–3′ ; Reaction temperature, 65◦C
MenA_F3 CGT AAA TGA AAT TTG GAC AG 20
MenA_B3 TTA TGA TCT TCT TCA TAG GGT A 22
MenA_FIP GAA CTC TAA TCT GAA CCA AAA TTG AGA GTT GAC ATG AAA CTC AGC ACA G 49
MenA_BIP CCT ACA GCT AAC AGA TAT TCT AGA AAA CGA ATA GTT TCG TAT GCC TTC 48
MenA_LF ATA GAT GAA CTT AAA GTT CT 20
MenA_LB GGA AGC ACT CTA TTA AAA ATA ATC 24
Serogroup B Sequence 5′–3′ ; Reaction temperature, 65◦C
MenB_F3 AAA CCC TCG GCT GGT AG 17
MenB_B3 CTT AAT AAT CTC TAA GTG TTC TTG 24
MenB_FIP GGC CAG GCC TAT AAT TCC TTC CTT TTC TAA TTG AGC CCC T 40
MenB_BIP CAC CCT CAA CCC AAT GTC TTT CTC ATT TCA GTG TTT TCC ACC 42
MenB_LB GGA GAG TTA ATT ATT AAC TTA ATT CAA 27
Serogroup C Sequence 5′–3′ ; Reaction temperature, 65◦C
MenC_F3 TGC TCT TCA ATT AAA GCG G 19
MenC_B3 GGT AAC AAT TAA TCC CCG TCT 21
MenC_FIP CCT ACT ACC CAA TGT CTG TCA ATT TTG TTG GGC TGT ATG GTG 42
MenC_BIP AGT CGA TGT CAG TCC AAT AAT TCC TGT AGT GAT TAA TGA ACC CCC T 46
MenC_LF GGG CAA ATC GTG ATT G 16
MenC_LB GGG TTG TTA AAT AAA TTA GTG G 22
Serogroup W Sequence 5′–3′ ; Reaction temperature, 64◦C
MenW_F3 GAC AAT AAG TTA CAA AAC CGT ATC 24
MenW_B3 TCA CCA GTT TTA AAA ACA CAA CC 23
MenW_FIP CTC ACT TTC TGA TGT CAT GAT CAG GTT ATT CAA AGG TGA ATC TTC CGA 48
MenW_BIP GGA AGG CAT GGT GTA TGA TAT TCC GTT ACT GTA ATC ATT CGC TCC 45
MenW_LF TCT GTA TTT TCA TAA ATT TCC TGC 24
Serogroup X Sequence 5′–3′ ; Reaction temperature, 63◦C
MenX_F3 GCC TTA TAC AAA GAC TGC G 19
MenX_B3 AAT AGG GGA TAG ATA ATT AGA GGT 24
MenX_FIP GCC GAG TGC TAA GAA AGT AGA ATC TCA ATC AAT TCC ACT TCA GGG A 46
MenX_BIP CCT GTT GTT GGC AAA GAA CTA CAA AAT GCA AAT TCA ATT GGT TGG 45
MenX_LF GTC AGG TAT CTT CTG AAA CTC AAA 24
MenX_LB ACC ATT GTA GCG GTC ATA AGT 21
Serogroup Y Sequence 5′–3′ ; Reaction temperature, 63◦C
MenY_F3 TGT CAA AAC CTC CAG C 16
MenY_B3 CGC TAA ACG ATA CAT TTC CA 20
MenY_FIP CGaG Gb TT TGA AGA ATT GTT GAT GGT GAC A TT CCA GAA AAT GTT AG 44
MenY_BIP CaACc TGC CCA CTA TAA GCA TGT TTT GAG TTG AAG AGG ATG AGT GA 44
MenY_LF GAA TAA AAA GGA ATA TTT CGG C 22
MenY_LB TCT TTA TTA TCT GAA GAA GAT AGC 24
aSpecific sequence of N. meningitidis serogroup Y; ARMS: boriginal sequence was C; coriginal sequence was G.
Clinical CSF Specimens
Children with suspected meningitis who were less than
5 years of age were prospectively enrolled at the participating
hospitals between 1998 and 2002 (Kim et al., 2012b). CSF
was streaked on commercial blood agar culture medium
(Becton, Dickinson & Co., Franklin Lakes, NJ, USA),
incubated in 5% CO2 at 37◦C for 3 days, and checked
daily for bacterial growth (Kim et al., 2012b). Isolates were
identiﬁed using standard microbiological criteria (Isenberg,
1998). The established multi-locus sequence typing (MLST)
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FIGURE 1 | Visual inspection of dye-mediated monitoring of the
N. meningitidis serogroup-specific loop-mediated isothermal
amplification (LAMP) assay. The original colorless appearance of the visual
inspection dye (Kaneka, Co., Ltd., Osaka, Japan) changed to blue if the
reaction was positive; if reaction was negative, the dye remained colorless.
(A), Results of N. meningitidis serogroup A-LAMP assay. (B), Results of
N. meningitidis serogroup B-LAMP assay. (C), Results of N. meningitidis
serogroup C-LAMP assay. (W), Results of N. meningitidis serogroup W-LAMP
assay. (X), Results of N. meningitidis serogroup X-LAMP assay. (Y), Results of
N. meningitidis serogroup Y-LAMP assay. NC, negative control.
scheme2 for Neisseria sp. was used for further genotype
identiﬁcation.
As described previously (Kim et al., 2012a; Lee et al., 2015),
to extract bacterial DNA, CSF specimens were heated at 95◦C
for 3 min and centrifuged at 13,000 × g for 5 min. The samples
were stored at −80◦C. Two microliters of the supernatant were
used for LAMP assays. In the previous study (Lee et al., 2015),
we had tested 1,574 randomly selected CSF specimens in Korea
(n = 470), China (n = 536), and Vietnam (n = 568) using the
Nm-LAMP assay targeting speciﬁc sequences of N. meningitidis
ctrA gene. In this study, we evaluated the serogroup identiﬁcation
LAMP assay using the set of 31 Nm-LAMP positive CSF
specimens.
Ethics Statement
We utilized CSF specimens preserved from our previous
surveillance study (Kennedy et al., 2007). All CSF specimens
utilized in this study were de-identiﬁed prior to laboratory
processing and analysis. Ethical approvals for patient specimen
collection during surveillance were obtained from the following
ethics review committees: the Institutional Review Board of
International Vaccine Institute, Seoul, Korea; the Institutional
Review Board at National Institute of Hygiene and Epidemiology,
Hanoi, Vietnam; and the Guangxi Zhuang Autonomous Region
2http://pubmlst.org/neisseria/
Center for Disease Control, Nanning, China. Each institution
participated in prospective, population-based surveillance for
childhood meningitis from 1999 to 2002 (Kim et al., 2004;
Anh et al., 2006). During those surveillance studies, written
consent was not obtained as the CSF collection was considered
routine standard care for hospitalized children with suspected
bacterial meningitis. For this reason, verbal consent of the parent
or legal guardian present with the child during the period of
hospitalization was recorded in the patient’s medical chart at the
time of the clinical lumbar puncture procedure. This consent
procedure was approved by these local scientiﬁc ethics review
committees of the participating institutions.
RESULTS
Specificity of the Serogroup
Identification LAMP Assay
To evaluate the species speciﬁcity of the N. meningitidis LAMP
primer set, we tested 35 reference strains, as described above.
When approximately 1-ng whole-cell DNA (106 copies of
genomic DNA of each strain) was used in the LAMP reaction,
ampliﬁcation products from each of the related serogroup strains
were observed within 30 min, whereas none of the other strains
resulted in ampliﬁcation products even after 60min of incubation
(Figure 1). We conﬁrmed that the ampliﬁcation products
corresponded to the selected sequence target by sequencing using
primers F2 and B2. The LAMP reaction is highly speciﬁc for each
serogroup.
Detection Limits of the Serogroup
Identification LAMP and PCR Assays
The detection limits for the LAMP assays were 10 or 100
genome copies and 100 to 1,000 CFUs (25 μL of reaction
mix, triplicate trials) as described in Table 2. The detection
limits of the PCR assays were 103 to 104 genome copies per
reaction (Table 2). Throughout the study, the evaluation of
the LAMP reactions showed complete agreement between a
white precipitate recorded by visual inspection, the real-time
turbidimeter, electrophoretic analysis, and LCV. Using LCV, the
colorless dye changed to blue color indicating a positive reaction.
These results were evaluable under natural light without the need
for UV light (Figure 1).
LAMP Applied to Analysis of Clinical CSF
Specimens
A group of 31 known Nm-LAMP-positive specimens (Lee
et al., 2015) were also analyzed by N. meningitidis serogroup-
speciﬁc LAMP tests. The LAMP assay identiﬁed N. meningitidis
serogroup for 29 of the 31 N. meningitidis-positive CSF
specimens (Table 3). Using a novel LAMP assay based on the
ARMS principle, we succeeded in diﬀerentiating N. meningitidis
serogroup Y from N. meningitidis serogroup W (Figure 1).
Five serogroup A (5/31, 16.1%), ﬁve serogroup B (5/31, 16.1%),
three serogroup C (3/31, 9.7%), ﬁve serogroup X (5/31, 16.1%),
ﬁve serogroup Y (5/31, 16.1%), and six serogroup W (6/31,
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TABLE 2 | Detection limits of the N. meningitidis serogroup-specific LAMP assay.
Detection limit of each N. meningitidis serogroup
Assay A B C W X Y
Each serogroup-specific LAMP 102 copiesa
102 cfub
102
102
102
103
10
102
102
102
102
102
Each serogroup-specific PCRc 103 copiesa 104 104 103 103 104
aAmount of DNA per reaction.
bAmount of colony forming units per reaction.
cConventional PCR (Fraisier et al., 2009).
TABLE 3 | Results of the serogroup-specific LAMP assay of 31 CSF samples of N. meningitidis ctrA positive.
N. meningitidis serogroup identified by LAMP
Country A B C W X Y Non-type Total
Vietnam 4a 4b 2 4 2 3 1 20
China 0 1 1 0 1 2 0 5
Korea 1 0 0 2 2 0 1 6
Total 5 5 3 6 5 5 2 31
aNumber of positive results.
bTwo strains were also found to be serogroup B contained MLST ST1576.
19.4%) specimens were identiﬁed. Two samples were non-
typable for N. meningitidis (2/31, 6.5%). Each serogroup-speciﬁc
LAMP-ampliﬁed product was conﬁrmed by sequencing, and the
sequence results were identical to the reference sequences.
In the previous study (Kennedy et al., 2007), three
N. meningitidis culture-positive (3/31, 9.7%) were conﬁrmed
and two of the three specimens were serogroup B positive using
MLST (Table 3). The MLST scheme and database of Neisseria sp.
are well-established and publically available at http://pubmlst.
org/neisseria/. The MLST scheme and methods previously
described were applied to the N. meningitidis isolates. Seven
MLST loci were ampliﬁed by using PCR primers and the DNA
sequences of each locus were compared to the same locus from
the database. Two serogroup B N. meningitidis isolates contained
an allele type 140, 5, 9, 173, 175, 34, 165 (in the order abcZ, adk,
aroE, fumC, gdh, pdhC, and pgm), which has been designated as
sequence type 1576 (ST1576).
Compared to the culture method, the sensitivity and speciﬁcity
of the N. meningitidis serogroup B LAMP assay were 100% (2/2)
and 89.7% (26/29).
DISCUSSION
The novel N. meningitidis serogroup-speciﬁc LAMP assay
reported here demonstrated high detection rates as well as
high test speciﬁcity and sensitivity. These higher detection rates
found with the LAMP assay compared with conventional PCR
is consistent with previous studies of LAMP assays (Kim et al.,
2011, 2012a). The robust performance of the LAMP assay is made
possible by the use of four diﬀerent primers to identify six distinct
regions on the target gene. The design of our primers for the
assay described here are unique and enable clear diﬀerentiation
between six major serogroups of N. meningitidis responsible
for invasive meningococcal disease (including meningitis) found
around the world.
We successfully diﬀerentiated N. meningitidis serogroup Y
from N. meningitidis serogroup W using the ARMS principle
(Newton et al., 1989). The ﬁrst application of ARMS in LAMP
primer design to detect a point mutation of target sequences
was reported by Ikeda et al. (2007). The investigator added one
mutation at the 5′ end of BIP primer that permitted successful
detection of the point mutation. In our experiments, optimizing
the design of the LAMP primer set for serogroup Y proved to
be challenging because key target gene sequences (synF from
serogroup Y and synG from serogroup W) share a high degree
of similarity that has been also noted by other investigators
(Zhu et al., 2012; Doyle and Jennison, 2013). To successfully
diﬀerentiate and accurately identify serogroup Y and W strains,
we created mutations at the 5′ end of both the FIP and BIP
primers.
The detection limits for the serogroup-speciﬁc LAMP assays
were 10 or 100 genome copies and 100 to 1,000 CFUs,
and the conventional PCR assays had much lower sensitivity
(103 to 104 genome copies) than LAMP. The evaluation of
the LAMP reactions showed complete agreement between a
white precipitate recorded by visual inspection, the real-time
turbidimeter, electrophoretic analysis, and LCV. The results of
LCV were evaluable under natural light without the need for UV
light and the color change remained visible for at least 1 week
(Lee et al., 2015). The experience using LCV colorimetric visual
inspection dye reported here can inform and facilitate future
development and application of the LAMP assay in resource-
limited settings.
We used preserved de-identiﬁed CSF specimens that were
collected between 1998 and 2002 in our previous study of
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bacterial meningitis (Kim et al., 2012b). In the previous study
(Lee et al., 2015), using 1574 randomly selected CSF specimens,
we detected 31 Nm-LAMP assay positive CSF specimens
including threeN.meningitidis culture-positive (3/31, 9.7%). Two
of the three specimens were conﬁrmed as serogroup B positive
using MLST.
Using the meningococcus serogroup-speciﬁc LAMP assay,
29 of the 31 known Nm-LAMP-positive specimens (Lee et al.,
2015) were one of six serogroup-speciﬁc positive CSF specimens.
Five serogroup A (5/31, 16.1%), ﬁve serogroup B (5/31, 16.1%),
three serogroup C (3/31, 9.7%), ﬁve serogroup X (5/31, 16.1%),
ﬁve serogroup Y (5/31, 16.1%), and six serogroup W (6/31,
19.4%) specimens were identiﬁed and two samples were non-
typable for N. meningitidis (2/31, 6.5%). In these results, the
observation of two non-typable specimens may be due to
potential discrepancies in the sensitivity of the Nm-LAMP (10
copies; Lee et al., 2015) compared with the N. meningitidis
serogroup-speciﬁc LAMP (10 or 100 copies) assays. Other
possible explanations for the observation of non-typable strains
include the degradation of DNA material in stored specimens as
well as the presence of N. meningitidis serogroups not covered by
designed LAMP assays.
In settings of many developing countries where empiric
use of broad-spectrum antibiotics is common, conventional
bacterial culture methods have low yield and are likely to
underestimate the true burden of N. meningitidis serogroups.
During the original prospective surveillance studies, ﬁeld
surveys showed that over-the-counter use of antibiotics
without a prescription was common in each country (Kim
et al., 2012b). Thus, to better understand the epidemiology
bacterial meningitis pathogens such as N. meningitidis, the
meningococcal serogroup-speciﬁc LAMP oﬀers an accurate
alternative diagnostic test. Our results suggest that the
meningococcal serogroup LAMP may provide a useful tool in
areas where public health agencies wish to measure the burden
of N. meningitidis following introduction of meningococcal
vaccines.
Based on our experience in this study, the N. meningitidis
serogroup-speciﬁc LAMP assay was easy to set-up and
required no special equipment. In addition, this LAMP
assay provides high-quality test results within 2 h that
make it feasible and cost-eﬀective for use. Given the
simple format for the LAMP assay, this test also has
potential for performance in district-level health facilities in
developing countries. To conﬁrm the LAMP assay performance
characteristics compared with bacterial culture, antigen
detection and PCR, further evaluation of the N. meningitidis
serogroup identiﬁcation LAMP in prospective studies are now
planned.
AUTHOR CONTRIBUTIONS
PK, HT, MO, DK, MS, contributed the conception of this study;
SM, JT, DK, MS designed the experiments; DL, EK, SM, DK, MS,
DO performed the experiments; PK, HT, MO acquired samples;
DL, EK, JT, SM, DO, PK, DK, MS analyzed data; DL, EK, JT,
SM, DO, PK, DK, MS interpreted data; DL, EK, PK, HT, DK,
MS drafted the manuscript; and DO, MO, SM, JT approved the
manuscript.
FUNDING
This work was supported by Japan Society for the Promotion
of Science (JSPS) KAKENHI Grant Number 10201004,
the grant 2015R1A2A2A01007297 from National Research
Foundation (NRF) of Korea, and the JSPS and NRF under
the Japan – Korea Basic Scientiﬁc Cooperation Program
(NRF-2014K2A2A4001480).
ACKNOWLEDGMENTS
We are grateful to Dr. Soon Ae Kim for her helpful advice. We
are especially grateful to Dr. Dang Duc Anh, National Institute of
Hygiene and Epidemiology, Hanoi, Vietnam; Dr. Bai Qing Dong,
Guangxi Zhuang Autonomous Region Health Bureau, Nanning,
Guangxi, China; and Prof. Jung Soo Kim, Chonbuk National
University School of Medicine, Jeonju, Korea for their support
in this study.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmicb.
2015.01548
REFERENCES
Alonso, J. M., Bertherat, E., Perea, W., Borrow, R., Chanteau, S., Cohet, C.,
et al. (2006). From genomics to surveillance, prevention and control: new
challenges for the African meningitis belt. Vaccine 24, 4279–4284. doi:
10.1016/j.vaccine.2006.03.037
Anh, D. D., Kilgore, P. E., Kennedy,W. A., Nyambat, B., Long, H. T., Jodar, L., et al.
(2006). Haemophilus influenzae type B meningitis among children in Hanoi,
Vietnam: epidemiologic patterns and estimates of H. Influenzae type B disease
burden. Am. J. Trop. Med. Hyg. 74, 509–515.
Borrow, R., Findlow, J., Gray, S., Taylor, S., and Kaczmarski, E. (2014). Safe
laboratory handling of Neisseria meningitidis. J. Infect. 68, 305–312. doi:
10.1016/j.jinf.2014.01.003
Campbell, H., Borrow, R., Salisbury, D., and Miller, E. (2009). Meningococcal C
conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl. 2),
B20–B29. doi: 10.1016/j.vaccine.2009.04.067
Chanteau, S., Dartevelle, S., Mahamane, A. E., Djibo, S., Boisier, P., and Nato, F.
(2006). New rapid diagnostic tests for Neisseria meningitidis serogroups A,
W135, C, and Y. PLoS Med. 3:e337. doi: 10.1371/journal.pmed.0030337
Chiavetta, L., Chavez, E., Ruzic, A., Mollerach, M., and Regueira, M. (2007).
[Surveillance of Neisseria meningitidis in Argentina, 1993-2005: distribution
of serogroups, serotypes and serosubtypes isolated from invasive disease]. Rev.
Argent. Microbiol. 39, 21–27.
Corless, C. E., Guiver, M., Borrow, R., Edwards-Jones, V., Fox, A. J., and
Kaczmarski, E. B. (2001). Simultaneous detection of Neisseria meningitidis,
Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of
Frontiers in Microbiology | www.frontiersin.org 7 January 2016 | Volume 6 | Article 1548
Lee et al. Meningococcal Serogroup Identification of LAMP
meningitis and septicemia using real-time PCR. J. Clin. Microbiol. 39, 1553–
1558. doi: 10.1128/JCM.39.4.1553-1558.2001
Doyle, C. J., and Jennison, A. V. (2013). Novel real-time polymerase chain
reactions for serogroup speciﬁc gene detection of Neisseria meningitidis
serogroups B, C, W-135 and Y. J. Microbiol. Methods 94, 83–85. doi:
10.1016/j.mimet.2013.04.011
Fraisier, C., Stor, R., Tenebray, B., Sanson, Y., and Nicolas, P. (2009). Use of a
new single multiplex PCR-based assay for direct simultaneous characterization
of six Neisseria meningitidis serogroups. J. Clin. Microbiol. 47, 2662–2666. doi:
10.1128/JCM.02415-08
Harrison, L. H., Trotter, C. L., and Ramsay, M. E. (2009). Global
epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51–B63.
doi: 10.1016/j.vaccine.2009.04.063
Harrison, O. B., Claus, H., Jiang, Y., Bennett, J. S., Bratcher, H. B., Jolley, K. A., et al.
(2013). Description and nomenclature of Neisseria meningitidis capsule locus.
Emerg. Infect. Dis. 19, 566–573. doi: 10.3201/eid1904.111799
Ikeda, S., Takabe, K., Inagaki, M., Funakoshi, N., and Suzuki, K. (2007). Detection
of gene point mutation in paraﬃn sections using in situ loop-mediated
isothermal ampliﬁcation. Pathol. Int. 57, 594–599. doi: 10.1111/j.1440-
1827.2007.02144.x
Isenberg, H. D. (1998). Essential Procedures for Clinical Microbiology. Washington,
DC: ASM Press.
Kennedy, W. A., Chang, S. J., Purdy, K., Le, T., Kilgore, P. E., Kim, J. S., et al.
(2007). Incidence of bacterial meningitis in Asia using enhanced CSF testing:
polymerase chain reaction, latex agglutination and culture. Epidemiol. Infect.
135, 1217–1226. doi: 10.1017/S0950268806007734
Kim, D. W., Kilgore, P. E., Kim, E. J., Kim, S. A., Anh, D. D., Dong, B. Q.,
et al. (2012a). The enhanced pneumococcal LAMP assay: a clinical tool for the
diagnosis of meningitis due to Streptococcus pneumoniae. PLoS ONE 7:e42954.
doi: 10.1371/journal.pone.0042954
Kim, S. A., Kim, D. W., Dong, B. Q., Kim, J. S., Anh, D. D., and Kilgore, P. E.
(2012b). An expanded age range for meningococcal meningitis: molecular
diagnostic evidence from population-based surveillance in Asia. BMC Infect.
Dis. 12:310. doi: 10.1186/1471-2334-12-310
Kim, D. W., Kilgore, P. E., Kim, E. J., Kim, S. A., Anh, D. D., and Seki, M.
(2011). Loop-mediated isothermal ampliﬁcation assay to detect Haemophilus
influenzae type b in cerebrospinal ﬂuid. J. Clin. Microbiol. 49, 3621–3626. doi:
10.1128/JCM.00515-11
Kim, J. S., Jang, Y. T., Kim, J. D., Park, T. H., Park, J. M., Kilgore,
P. E., et al. (2004). Incidence of Haemophilus influenzae type b and other
invasive diseases in South Korean children. Vaccine 22, 3952–3962. doi:
10.1016/j.vaccine.2004.04.003
Kristiansen, P. A., Ba, A. K., Ouedraogo, A. S., Sanou, I., Ouedraogo, R., Sangare, L.,
et al. (2014). Persistent low carriage of serogroup A Neisseria meningitidis
two years after mass vaccination with the meningococcal conjugate vaccine,
MenAfriVac. BMC Infect. Dis. 14:663. doi: 10.1186/s12879-014-0663-4
Ladhani, S. N., Flood, J. S., Ramsay, M. E., Campbell, H., Gray, S. J., Kaczmarski,
E. B., et al. (2012). Invasive meningococcal disease in England and Wales:
implications for the introduction of new vaccines. Vaccine 30, 3710–3716. doi:
10.1016/j.vaccine.2012.03.011
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F.,
Sumpradit, N., et al. (2013). Antibiotic resistance-the need for global solutions.
Lancet Infect. Dis. 13, 1057–1098. doi: 10.1016/S1473-3099(13)70318-9
Lee, D. K., Kim, E. J., Kilgore, P. E., Kim, S. A., Takahashi, H., Ohnishi, M.,
et al. (2015). Clinical evaluation of a Loop-Mediated Isothermal Ampliﬁcation
(LAMP) assay for rapid detection of Neisseria meningitidis in cerebrospinal
ﬂuid. PLoS ONE 10:e0122922. doi: 10.1371/journal.pone.0122922
Levy, S. B., and Marshall, B. (2004). Antibacterial resistance worldwide: causes,
challenges and responses.Nat. Med. 10, S122–S129. doi: 10.1038/nm1145
Miyamoto, S., Sano, S., Takahashi, K., and Jikihara, T. (2015). Method
for colorimetric detection of double-stranded nucleic acid using
leuco triphenylmethane dyes. Anal. Biochem. 473, 28–33. doi:
10.1016/j.ab.2014.12.016
Mori, Y., Kitao, M., Tomita, N., and Notomi, T. (2004). Real-time turbidimetry
of LAMP reaction for quantifying template DNA. J. Biochem. Biophys.
Methods 59, 145–157. doi: 10.1016/j.jbbm.2003.12.005S0165022X030
02173
Newton, C. R., Graham, A., Heptinstall, L. E., Powell, S. J., Summers, C.,
Kalsheker, N., et al. (1989). Analysis of any point mutation in DNA. The
ampliﬁcation refractory mutation system (ARMS).Nucleic Acids Res. 17, 2503–
2516. doi: 10.1093/nar/17.7.2503
Notomi, T., Mori, Y., Tomita, N., and Kanda, H. (2015). Loop-mediated isothermal
ampliﬁcation (LAMP): principle, features, and future prospects. J. Microbiol. 53,
1–5. doi: 10.1007/s12275-015-4656-9
Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T.,Watanabe, K., Amino, N.,
et al. (2000). Loop-mediated isothermal ampliﬁcation of DNA. Nucleic Acids
Res. 28, E63. doi: 10.1093/nar/28.12.e63
Stephens, D. S. (2009). Biology and pathogenesis of the evolutionarily successful,
obligate human bacterium Neisseria meningitidis. Vaccine 27(Suppl. 2), B71–
B77. doi: 10.1016/j.vaccine.2009.04.070
Stephens, D. S., Greenwood, B., and Brandtzaeg, P. (2007). Epidemic meningitis,
meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196–2210. doi:
10.1016/S0140-6736(07)61016-2
Taha, M. K., Alonso, J. M., Caﬀerkey, M., Caugant, D. A., Clarke, S. C., Diggle,
M. A., et al. (2005). Interlaboratory comparison of PCR-based identiﬁcation
and genogrouping ofNeisseria meningitidis. J. Clin. Microbiol. 43, 144–149. doi:
10.1128/JCM.43.1.144-149.2005
Tettelin, H., Saunders, N. J., Heidelberg, J., Jeﬀries, A. C., Nelson, K. E., Eisen,
J. A., et al. (2000). Complete genome sequence of Neisseria meningitidis
serogroup B strain MC58. Science 287, 1809–1815. doi: 10.1126/science.287.
5459.1809
Tomita, N., Mori, Y., Kanda, H., and Notomi, T. (2008). Loop-mediated isothermal
ampliﬁcation (LAMP) of gene sequences and simple visual detection of
products. Nat. Protoc. 3, 877–882. doi: 10.1038/nprot.2008.57
Verma, R., and Khanna, P. (2012). Meningococcal vaccine: a new vaccine to
combat meningococcal disease in India. Hum. Vaccin. Immunother. 8, 1904–
1906. doi: 10.4161/hv.21666
WHO (2011). Meningococcal vaccines: WHO position paper, November 2011.
Wkly Epidemiol. Rec. 86, 521–539.
Zhu, H., Wang, Q., Wen, L., Xu, J., Shao, Z., Chen, M., et al. (2012). Development
of a multiplex PCR assay for detection and genogrouping of Neisseria
meningitidis. J. Clin. Microbiol. 50, 46–51. doi: 10.1128/JCM.00918-11
Conflict of Interest Statement: Mitsuko Seki has received research grant funding
from Kaneka, Co., Ltd. Jun Tomono and Shigehiko Miyamoto are employees of
Kaneka, Co., Ltd. Paul E. Kilgore serves onmeningococcal vaccine speakers bureau
for Pﬁzer, Inc. The following authors have no conﬂict of interests or ﬁnancial
disclosures to declare: DoKyung Lee, Eun Jin Kim, Hideyuki Takahashi, Makoto
Ohnishi, and DongWook Kim. These statements do not alter our adherence to the
journal policies on sharing data and materials.
Copyright © 2016 Lee, Kim, Kilgore, Takahashi, Ohnishi, Tomono, Miyamoto,
Omagari, Kim and Seki. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 8 January 2016 | Volume 6 | Article 1548
